





ELI LILLY AND COMPANY  
**Q4 2025 EARNINGS CALL**



# Agenda

## Introduction and Key Events

Dave Ricks, Chair and Chief Executive Officer

## Q4 2025 Financial Results & 2026 Financial Guidance

Lucas Montarce, Chief Financial Officer

## R&D Update

Dan Skovronsky, M.D., Ph.D., Chief Scientific and Product Officer

## Question & Answer Session

# Safe Harbor Provision and Other Information

This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; litigation and investigations; business development transactions; trade and economic conditions; the negotiation and implementation of our voluntary agreement with the U.S. government related to drug pricing and access; and changes in laws and regulations, including healthcare reform.

For additional information about the factors that affect the company's business, please see the company's latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission. Certain financial information in this presentation is presented on a non-GAAP basis. Investors should refer to the reconciliations included in this presentation and should consider the company's non-GAAP measures in addition to, not as a substitute for or superior to, measures prepared in accordance with GAAP. These materials are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval or become commercially available for the uses being investigated.

**The company undertakes no duty to update forward-looking statements except as required by applicable law.**

# Q4 2025 Summary

## Deliver Revenue Growth

Robust **revenue growth of 43%** driven by **Key Products**<sup>1</sup>

U.S. incretin analogs **market grew 33%**, Lilly share of market increased to **60.5%**<sup>2</sup>

Revenue **outside the U.S. grew 43%**, driven by Mounjaro

## Invest in Future Innovation

**New manufacturing investments in Huntsville, AL, Lehigh Valley, PA and the Netherlands**

Expanded NVIDIA collaboration with a **Co-Innovation AI Lab**

Entered into agreement to acquire **Ventyx Biosciences**

## Speed Life-Changing Medicines

Full U.S. FDA approval and expanded indication for **Jaypirca**

Phase 3 topline data for **retatrutide** in knee osteoarthritis pain and obesity

Phase 3 topline data for **orforglipron** in maintenance setting


Orforglipron now submitted in more than **40 countries** worldwide

<sup>1</sup> Key products include Ebglyss, Inluriyo (effective Q4 2025), Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio and Zepbound

<sup>2</sup> IQVIA NPA total prescriptions, rolling four week data December 26, 2025; Incretin analogs market includes: injectable GLP-1s, oral GLP-1s and GLP-1/GIP dual agonists

Note: Growth rates reflect change vs. Q4 2024

# Strategic Deliverables



Note: Total revenue, key product revenue, research and development, marketing, selling and administrative, and Non-GAAP EPS growth rates reflect change vs. Q4 2024  
PsA=psoriatic arthritis; CLL=Chronic Lymphocytic Leukemia; SLL=Small Lymphocytic Lymphoma

2025 Q4 EARNINGS

Not for promotional use

# Q4 2025 Key Income Statement Measures (unaudited)

Dollars in millions; except per share data

**Q4 2025**

	GAAP Reported	Adjustments	Non-GAAP Adjusted	YoY Non-GAAP Adjusted Change
<b>TOTAL REVENUE</b>	<b>\$19,292</b>	\$ -	<b>\$19,292</b>	43%
<b>GROSS MARGIN</b>	<b>82.5%</b>	0.7 pp	<b>83.2%</b>	0.0pp
<b>TOTAL OPERATING EXPENSE</b>	<b>\$7,547</b>	\$ (84)	<b>\$7,463</b>	32%
<b>OPERATING INCOME</b>	<b>\$8,373</b>	\$208	<b>\$8,581</b>	52%
<b>OTHER INCOME (EXPENSE)</b>	<b>\$(108)</b>	\$(39)	<b>\$(147)</b>	58%
<b>EFFECTIVE TAX RATE</b>	<b>19.7%</b>	0.0pp	<b>19.7%</b>	6.5pp
<b>NET INCOME</b>	<b>\$6,636</b>	\$135	<b>\$6,771</b>	41%
<b>EPS</b>	<b>\$7.39</b>	\$0.15	<b>\$7.54</b>	42%
<b>Acquired IPR&amp;D Charge per share<sup>1</sup></b>	<b>\$0.52</b>	\$ -	<b>\$0.52</b>	<b>174%</b>

<sup>1</sup> Acquired IPR&D (in-process research and development) charge of \$529 million (pre-tax). Numbers may not add due to rounding

<b>Performance Margin<sup>2</sup></b>	<b>46.1%</b>	<b>47.2%</b>	<b>+4.2pp</b>
---------------------------------------	--------------	--------------	---------------

<sup>2</sup> The Company defines Performance Margin as gross margin less research and development, marketing, selling and administrative, and asset impairment, restructuring and other special charges divided by revenue  
Note: The Non-GAAP Performance Margin excludes the amortization of intangible assets. The applicable impact of amortization of intangible assets can be found in the reconciliation tables on slide 23.

# Price/Rate/Volume Effect on Revenue

Dollars in millions

**Q4 2025**

	Amount	Price	FX Rate	Volume	Total	CER
U.S.	\$12,877	(7)%	-	50%	43%	43%
EUROPE	\$3,096	1%	6%	19%	26%	20%
JAPAN	\$654	(1)%	(2)%	20%	17%	19%
CHINA	\$474	(1)%	0%	11%	10%	10%
REST OF WORLD	\$2,190	1%	2%	102%	106%	104%
<b>TOTAL REVENUE</b>	<b>\$19,292</b>	<b>(5)%</b>	<b>1%</b>	<b>46%</b>	<b>43%</b>	<b>41%</b>

Dollars in millions


**FY 2025**

	Amount	Price	FX Rate	Volume	Total	CER
U.S.	\$43,481	(10)%	-	53%	43%	43%
EUROPE	\$11,558	(0)%	5%	62%	67%	62%
JAPAN	\$2,132	(0)%	1%	17%	17%	16%
CHINA	\$1,951	1%	(0)%	17%	18%	18%
REST OF WORLD	\$6,057	0%	(1)%	42%	42%	42%
<b>TOTAL REVENUE</b>	<b>\$65,179</b>	<b>(6)%</b>	<b>1%</b>	<b>50%</b>	<b>45%</b>	<b>44%</b>

Numbers may not add due to rounding

CER = price change + volume change

# Q4 2025 Update on Key Products



## Key Product Highlights:

### **MOUNJARO**

U.S. type 2 diabetes incretin analogs SOM leader with TRx SOM 48% and NBRx SOM 55% at end of Q4 2025

International revenue grew 10% vs. Q3 2025

### **ZEPBOUND**

U.S. branded anti-obesity SOM leader with TRx SOM 64% and NBRx SOM 69% at end of Q4 2025

### **VERZENIO**

Q4 2025 sales of \$1.6B; sales increased 3% vs. Q4 2024  
International volume grew 16% vs. Q4 2024

### **JAYPIRCA**

Q4 2025 sales of \$148M; sales increased 30% vs. Q4 2024

### **INLURIYO**

Q4 2025 sales of \$14M following U.S. launch

### **EBGLYSS**

Q4 2025 sales of \$134M; U.S. TRx grew 25% vs. Q3 2025


### **OMVOH**

Q4 2025 sales of \$88M; US TRx grew 22% vs. Q3 2025

### **KISUNLA**

Q4 2025 sales of \$109M grew 54% vs. Q3 2025

# U.S. Incretin Analogs Market



Source: IQVIA weekly NPA total prescriptions, weekly data December 26, 2025; Incretin analogs market includes: injectable GLP-1s, oral GLP-1s and GLP-1/GIP dual agonists

Lilly

2025 Q4 EARNINGS

## Incretin Analogs Market Key Highlights:

**U.S. market grew 33% in Q4 vs. prior year and 6% vs. Q3 2025**


**Lilly share of market increased to 60.5%, +2.6pp vs. prior quarter**

**Announced agreement with the U.S. government to expand access in 2026**

# Capital Allocation

\$ in billions

## FY 2025 Capital Allocation



\* After tax

\*\* Includes development milestones, closed acquisitions and cash outflows associated with equity investments

# Select Factors Influencing 2026 Financial Outlook

Favorable	Unfavorable
Continued momentum from Mounjaro and Zepbound worldwide	Global pricing decline in low- to mid-teens driven by: <ul style="list-style-type: none"><li>○ Access agreement with the U.S. government</li><li>○ New Zepbound direct-to-patient pricing</li><li>○ Mounjaro reimbursement in China for type 2 diabetes</li><li>○ Medicaid MFN pricing impact on later lifecycle products</li></ul>
Expanded obesity medicine access in Medicare expected by July 1, 2026	
Growth from key products including Ebglyss, Omvoh, Jaypirca, Inluriyo, and Kisunla	Flat or eroding contributions from later lifecycle products including Taltz, Trulicity, and Verzenio
Expected orforglipron U.S. launch in Q2, pending FDA approval	Acceleration of R&D expense growth driven by announced and planned investments in the portfolio

MFN: Most Favored Nation



# 2026 Guidance (Non-GAAP)

	2025 Non-GAAP Adjusted	2026 Guidance	2026 Comments
REVENUE <sup>1</sup>	\$65.2 billion	\$80.0 – \$83.0 billion	Midpoint represents 25% growth
PERFORMANCE MARGIN <sup>2</sup>	46.3%	46.0% – 47.5%	Gross Margin will be stable to slightly down, with favorable product mix and productivity offset by price and new facilities  Research and development expense will continue to accelerate, driven by ongoing and new late-phase programs
TAX RATE	18.4%	Approximately 18-19%	
EARNINGS PER SHARE <sup>3</sup>	\$24.21	\$33.50 – \$35.00	

<sup>1</sup> GAAP measure


<sup>2</sup> The Company defines Performance Margin as gross margin less research and development and marketing, selling, and administrative expenses divided by revenue. Excludes the impact of intangible asset amortization

<sup>3</sup> 2026 assumes shares outstanding of approximately 894 million


FX assumptions of 1.16 (Euro), 153 (Yen) and 7.1 (Yuan)

# TOGETHER-PsA Topline Phase 3b Results

## ACR50 and $\geq 10\%$ Weight Reduction at 36 Weeks



## ACR50 at 36 Weeks



## Key Highlights:

Concomitant use of Taltz and Zepbound delivered superior results to Taltz monotherapy

Regimen delivered 64% relative increase in proportion of patients who achieved ACR50 vs. Taltz monotherapy

>60% of patients had prior experience with advanced therapies

Adverse events in participants treated with concomitant therapy were consistent with the known safety profile of each medicine

\*\* P value  $\leq 0.001$ . Hypothetical efficacy estimand in the modified intent-to-treat (mITT) population. Represents efficacy in all mITT participants who remained on study intervention without initiating prohibited medication


\* P value  $\leq 0.05$ . Hypothetical efficacy estimand in the mITT population

PsA=psoriatic arthritis; ACR50=American College of Rheumatology 50

# Pirtobrutinib Progression Free Survival in Treatment-Naïve CLL


## BRUIN CLL-313 ITT<sup>1</sup>

**80%** reduction in risk of progression or death  
vs BendaR



## BRUIN CLL-314 TN Subgroup<sup>2</sup>

**76%** reduction in risk of progression or death  
vs ibrutinib



Pirtobrutinib safety and tolerability consistent with other Phase 3 trials, with low rates of discontinuation and atrial fibrillation/flutter


<sup>1</sup> PFS results presented are IRC assessed

<sup>2</sup> PFS results presented are INV assessed; PFS data immature at time of readout


CLL: Chronic lymphocytic leukemia; ITT: Intent to Treat; TN: Treatment Naïve; BendaR: Bendamustine plus rituximab; IRC: Independent Review Committee; INV: Investigator

# Orforglipron ATTAIN-MAINTAIN Topline Results

## Semaglutide<sup>1</sup> to Orforglipron



## Tirzepatide<sup>1</sup> to Orforglipron



## Key Highlights:

Orforglipron met primary and all key secondary endpoints

Patients switching from semaglutide to orforglipron lost weight at 24 weeks (-0.1 kg) vs regain on placebo (9.4kg)

Safety and tolerability profile consistent with previous orforglipron Phase 3 studies

Could provide patients a convenient option for their long-term health journey


<sup>1</sup> Treatment was at maximum tolerated doses of either 1.7 mg or 2.4 mg (semaglutide) or 10 mg or 15 mg (tirzepatide)

<sup>2</sup> Observed mean based on efficacy estimand data set

<sup>3</sup> Mixed Model for Repeated Measures (MMRM) based on efficacy estimand data set

# Retatrunotide TRIUMPH-4 Topline Results

## Co-Primary Endpoint Change at 68 Weeks



Discontinuation rates due to AEs 4-18% across all participants and 5-12% in participants with BMI  $\geq 35$

WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index pain score; Percent change in the WOMAC pain subscale score and percent change in the WOMAC physical function subscale score were not pre-specified and were estimated from a post-hoc analysis

## Key Highlights:

Participants taking retatrunotide 12 mg lost an average of 71 pounds

Retatrunotide reduced WOMAC pain scores by up to an average of 75.8%

1 out of 8 participants were completely free from knee pain


Most common adverse events were consistent with those seen in clinical trials for other incretins

# Lilly Select Pipeline

February 3, 2026

VEPUGRATINIB <i>Cancer</i>	TARGETS UNDISCLOSED <i>Sixteen Additional NMEs</i>
TERSOLISIB (PI3K $\alpha$ INH) <i>Cancer</i>	UNC13A SSO <i>ALS</i>
SMARCA2 (BRM) <i>Cancer</i>	SNCA siRNA <i>Neurodegeneration</i>
PTK7 ADC <i>Cancer</i>	SARM1 INHIBITOR <i>Neurodegeneration</i>
PCSK9 EDITOR <i>ASCVD</i>	PNPLA3 siRNA <i>MASLD</i>
NECTIN-4 ADC 2 <i>Cancer</i>	PAN KRAS <i>Cancer</i>
NAV 1.8 INH (SM) <i>Pain</i>	NECTIN-4 ADC 1 <i>Cancer</i>
LA-ANP <i>Heart Failure</i>	MAPT siRNA <i>Neurodegeneration</i>
INTEGRIN $\alpha$ 5 $\beta$ 1 <i>CMH</i>	KRAS G12D <i>Cancer</i>
GGG TRI-AGONIST III <i>CMH</i>	GS INSULIN RECEPTOR AGONIST II <i>Diabetes</i>
AT2R ANTAGONIST <i>Pain</i>	FXR AGONIST <i>Immunology</i>
ANGPTL3 EDITOR <i>ASCVD</i>	ANTI-VEGF GENE THERAPY <i>Vestibular Schwannoma</i>

RETATRUTIDE <i>MASLD</i>	TIRZEPATIDE <i>MASLD</i>
ORFORGLIPRON <i>CV Outcomes</i>	ORFORGLIPRON <i>PAD</i>
TIRZEPATIDE <i>MMO</i>	TIRZEPATIDE <i>Type 1 Diabetes</i>
RETATRUTIDE <i>Diabetes</i>	SELPERCATINIB <i>Adjuvant RET+ NSCLC</i>
RETATRUTIDE <i>CLBP</i>	RETATRUTIDE <i>CV / Renal Outcomes</i>
PIRTOBRUTINIB <i>R/R CLL Combination</i>	PIRTOBRUTINIB <i>R/R MCL Monotherapy</i>
ORFORGLIPRON <i>Osteoarthritis Pain</i>	ORFORGLIPRON <i>Stress Urinary Incontinence</i>
ORFORGLIPRON <i>Hypertension</i>	ORFORGLIPRON <i>Obstructive Sleep Apnea</i>
OLOMORASIB <i>Adj KRAS G12C+ NSCLC (resected)</i>	OLOMORASIB <i>Adj KRAS G12C+ NSCLC (unresected)</i>
MIRIKIZUMAB + TIRZEPATIDE <i>UC</i>	OLOMORASIB <i>1L KRAS G12C+ NSCLC (PD-L1 high)</i>
LEBRIKIZUMAB <i>CRSwNP</i>	MIRIKIZUMAB + TIRZEPATIDE <i>CD</i>
IXEKIZUMAB + TIRZEPATIDE <i>Psoriasis</i>	LEBRIKIZUMAB <i>AR (perennial allergens)</i>
IMLUNESTRANT <i>Adjuvant Breast Cancer</i>	IXEKIZUMAB + TIRZEPATIDE <i>PsA</i>
SOFETABART MIPITECAN (FRa ADC) <i>PROC</i>	DONANEMAB <i>Preclinical Alzheimer's Disease</i>
ELORALINTIDE <i>Obesity</i>	IXO-VEC <i>wet AMD</i>
RETATRUTIDE <i>Obesity, OA, OSA</i>	BRENIPATIDE <i>AUD</i>
OLOMORASIB <i>1L KRAS G12C+ NSCLC (All PD-L1)</i>	REMLERNETUG <i>Preclinical / MCI AD</i>
LEPODISIRAN <i>ASCVD</i>	MUVALAPLIN <i>ASCVD</i>
	TIRZEPATIDE <i>CV Outcomes</i>
	PIRTOBRUTINIB <i>1L CLL Monotherapy</i>
	ORFORGLIPRON <i>Diabetes</i>
	ORFORGLIPRON <i>Obesity</i>
	INSULIN EFSITORA ALFA <i>Diabetes</i>
	TIRZEPATIDE <i>Heart Failure pEF</i>



# Key Events 2025

NEW SINCE LAST UPDATE

## PHASE 3 INITIATIONS

- ✓+ Orforglipron for hypertension and overweight or obesity
- ✓+ Olomorrasib for resected adjuvant NSCLC<sup>1</sup>
- ✓+ Muvalaplin for ASCVD<sup>2</sup>
- ✓+ Retatrutide for chronic low back pain and overweight or obesity
- ✓+ Olomorrasib for unresected NSCLC<sup>1</sup>
- ✓+ Tirzepatide for type 1 diabetes
- ✓+ Orforglipron for OA<sup>3</sup> pain of the knee and overweight or obesity
- ✓+ Retatrutide and Tirzepatide for MASLD<sup>4</sup>
- ✓+ Orforglipron for SUI<sup>5</sup> and overweight or obesity
- ✓+ Brenipatide for AUD<sup>6</sup>
- ✓+ Orforglipron for cardiovascular outcomes

## PHASE 3 DATA DISCLOSURES

- ✓+ Orforglipron for obesity [ATTAIN-1 ✓+ / 2 ✓+]
- ✓+ Orforglipron for type 2 diabetes [ACHIEVE-1 ✓+ / 2 ✓+ / 3 ✓+ / 5 ✓+]
- ✓+ Tirzepatide cardiovascular outcomes [SURPASS-CVOT]
- ✓+ Pirtobrutinib 1L CLL vs. BR<sup>7</sup> [BRUIN CLL-313]
- ✓+ Pirtobrutinib 1L CLL vs. ibrutinib [BRUIN CLL-314]
- ✓+ Retatrutide for OA<sup>3</sup> pain of the knee and overweight or obesity [TRIUMPH-4]
- ✓+ Orforglipron for maintenance of body weight reduction [ATTAIN-MAINTAIN]

## REGULATORY SUBMISSIONS

- ✓+ Insulin efsitora alfa for type 2 diabetes [US ✓+ / EU ✓+ / J ✓+]
- ✓+ Orforglipron for obesity [US ✓+ / EU ✓+ / J ✓+]
- ✓+ Tirzepatide for cardiovascular outcomes [US ✓+]
- ✓+ Pirtobrutinib CLL full approval [US ✓+]
- ✓+ Pirtobrutinib for 1L CLL [US ✓+ / EU ✓+]
- ✓+ Tirzepatide for Pediatric and Adolescent type 2 diabetes [US ✓+ / EU ✓+]

## REGULATORY ACTIONS

- ✓+ Mirikizumab for Crohn's disease [US ✓+ / EU ✓+ / J ✓+]
- Tirzepatide for HFpEF [US ✓- / EU ✓+]
- ✓+ Tirzepatide for pediatric patients and adolescent T2D [US ✓+ / EU ✓+]
- ✓+ Imlunestrant ER+, HER2- mBC [US ✓+ / J ✓+]
- ✓+ Pirtobrutinib for CLL full approval [US ✓+ / EU ✓+ / J ✓+]
- ✓+ Donanemab for early Alzheimer's disease [EU]

<sup>1</sup> Non-small cell lung cancer; <sup>2</sup> Atherosclerotic cardiovascular disease; <sup>3</sup> Osteoarthritis; <sup>4</sup> Metabolic dysfunction-associated steatotic liver disease; <sup>5</sup> Stress Urinary Incontinence; <sup>6</sup> Alcohol use disorder; <sup>7</sup> Bendamustine plus Rituximab

Not for promotional use

# Potential Key Events 2026

NEW SINCE LAST UPDATE

## PHASE 3 INITIATIONS

✓+ Eloraliotide for overweight or obesity

✓+ Orforglipron for peripheral artery disease

Vepugratinib for 1L metastatic urothelial cancer

Tersolisib for advanced breast cancer

✓+ Sofetabart Mipitecan for platinum-resistant ovarian cancer

Sofetabart Mipitecan for platinum-sensitive ovarian cancer

Brenipatide for major depressive disorder

Baricitinib for Type 1 Diabetes

## PHASE 3 DATA DISCLOSURES

✓+ Ixekizumab and Tirzepatide for psoriatic arthritis and overweight or obesity

Orforglipron for T2D [ACHIEVE-4]

Orforglipron for obstructive sleep apnea

Retatrutide for overweight or obesity [TRIUMPH 1/2/3]

Retatrutide for T2D [TRANSCEND-T2D 1/2/3]

Lebrikizumab for pediatric atopic dermatitis

Pirtobrutinib for R/R CLL combination [BRUIN-322]

## REGULATORY SUBMISSIONS

Orforglipron for T2D [US / EU ✓+/ J]

Orforglipron for obstructive sleep apnea and overweight or obesity

Retatrutide for overweight or obesity

Retatrutide for obstructive sleep apnea and overweight or obesity

Retatrutide for osteoarthritis pain of the knee and overweight or obesity

Pirtobrutinib for R/R CLL combination

Lebrikizumab for pediatric atopic dermatitis



A close-up photograph of a female scientist in a laboratory. She is wearing a white lab coat with a name tag that says "Lilly" in red cursive script, a white lab coat, and safety goggles. She is looking through a microscope, and her hands are wearing white gloves. The background is blurred, showing other laboratory equipment and shelves.

# Supplemental Slides

# 2025 Income Statement – Reported

Dollars in millions; except per share data

	Q4 2025	Change
<b>TOTAL REVENUE</b>	<b>\$19,292</b>	43%
<b>GROSS MARGIN</b>	<b>82.5%</b>	0.3pp
<b>TOTAL OPERATING EXPENSE*</b>	<b>\$7,547</b>	26%
<b>OPERATING INCOME</b>	<b>\$8,373</b>	63%
<b>OPERATING MARGIN</b>	<b>43.4%</b>	5.4pp
<b>OTHER INCOME (EXPENSE)</b>	<b>\$(108)</b>	(2)%
<b>EFFECTIVE TAX RATE</b>	<b>19.7%</b>	7.2pp
<b>NET INCOME</b>	<b>\$6,636</b>	50%
<b>EPS</b>	<b>\$7.39</b>	51%

\* Includes research and development expense; marketing, selling and administrative; acquired in-process research and development charges; and asset impairment, restructuring and other special charges (as applicable)

# EPS Reconciliation

	Q4 2025	Q4 2024	% Change
EARNINGS PER SHARE (REPORTED)	\$7.39	\$4.88	51%
AMORTIZATION OF INTANGIBLE ASSETS	0.11	0.12	(8)%
ASSET IMPAIRMENT, RESTRUCTURING AND OTHER SPECIAL CHARGES	0.07	0.30	(77)%
NET LOSSES (GAINS) ON INVESTMENTS IN EQUITY SECURITIES	(0.03)	0.02	NM
EARNINGS PER SHARE (NON-GAAP)	\$7.54	\$5.32	42%
ACQUIRED IPR&D	\$0.52	\$0.19	174%

Numbers may not add due to rounding; see slide 24 for more details on these adjustments; NM = not meaningful

# Q4 Non-GAAP Adjustments

## Q4 2025 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO EXCLUDE:

- amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling \$124 million (pre-tax), or \$0.11 per share (after-tax)
- asset impairment, restructuring and other special charges totaling \$84 million (pre-tax), or \$0.07 per share (after-tax)
- net gains on investments in equity securities totaling \$39 million (pre-tax), or (\$0.03) per share (after-tax)

## Q4 2024 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO EXCLUDE:

- asset impairment, restructuring and other special charges totaling \$344 million (pre-tax), or \$0.30 per share (after-tax)
- amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling \$136 million (pre-tax), or \$0.12 per share (after-tax)
- net losses on investments in equity securities totaling \$17.0 million (pre-tax), or \$0.02 per share (after-tax)


# Q4 2025 Mounjaro Sales Increased \$3.9B

\$ in Millions

**U.S. sales were \$4.1 billion**  
**International sales were \$3.3 billion**



**U.S. TRx SOM and Market Volume**




Source: IQVIA NPA TRx 3MMA, weekly data December 26, 2025; RA = rolling average  
TRx data is representative of the injectable incretin type 2 diabetes market


# Q4 2025 Zepbound Sales Increased \$2.4B

\$ in Millions

**U.S. sales were \$4.2 billion**  
**International sales were \$31 million<sup>1</sup>**



## U.S. TRx SOM and Market Volume



<sup>1</sup> Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the United States

Source: IQVIA NPA TRx 3MMA, weekly data December 26, 2025; RA = rolling average  
TRx data is representative of the branded anti-obesity market


# Q4 2025 Verzenio Sales Increased 3%

\$ in Millions

**U.S. sales were \$997 million**  
**International sales were \$608 million**



**U.S. TRx SOM and Market Volume**



Source: IQVIA NPA TRx 3MMA, weekly data December 26, 2025; RA = rolling average

# Select Trials – Brenipatide

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<a href="#">NCT07219966</a>	Alcohol Use Disorder	A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)	3	1100	Change in Drinking Patterns in Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method (TLFB)	Apr 2028	Apr 2028
<a href="#">NCT07219953</a>	Alcohol Use Disorder	A Study of Brenipatide in Participants With Alcohol Use Disorder (RENEW-ALC-2)	3	1100	Change in Drinking Patterns in Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method (TLFB)	Apr 2028	Apr 2028
<a href="#">NCT07223840</a>	Tobacco Use Disorder	A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse (RENEW-Smk-1)	2	222	Percentage of Participants that Achieve Carbon Monoxide (CO)-Confirmed Continuous Abstinence from Cigarette Smoking with Allowed Slips	Feb 2027	Feb 2027
<a href="#">NCT07286175</a>	Bipolar Disorder	A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)	2	400	Time to Relapse Defined as Days from Randomization to the Date on Which the Participant Meets Any Relapse Criterion	Nov 2027	Nov 2027
<a href="#">NCT07219173</a>	Asthma	A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma	2	531	Annualized Asthma Exacerbation Rate Over 52 Weeks of Treatment, To assess the asthma exacerbation rate	Apr 2028	Jun 2028

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Donanemab

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<a href="#">NCT04437511</a>	Alzheimer's Disease	A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)	3	1736	Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Overall Population)	Apr 2023	Nov 2028
<a href="#">NCT05738486</a>	Alzheimer's Disease	A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)	3	1175	Percentage of Participants with Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E)	May 2024	May 2027
<a href="#">NCT05508789</a>	Alzheimer's Disease	A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)	3	1500	Change from Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS)	May 2028	July 2028
<a href="#">NCT05026866</a>	Alzheimer's Disease	A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)	3	2996	Time to Clinical Progression of Composite Endpoint as Measured by Clinical Dementia Rating (CDR)	Nov 2027	Nov 2027

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Eloraintide

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<a href="#">NCT07282600</a>	Obesity	A Study of Eloraintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes (ENLIGHTEN-2)	3	1035	Percent Change from Baseline in Body Weight	Jan 2028	Feb 2028
<a href="#">NCT06603571</a>	Obesity	A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes	2	350	Percent Change from Baseline in Body Weight	Jun 2026	Aug 2026

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Imlunestrant

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<a href="#">NCT04975308</a>	Breast Neoplasms	A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3)	3	874	Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B)	Jun 2024	Aug 2027
<a href="#">NCT05514054<sup>1</sup></a>	Breast Neoplasms	A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)	3	8000	Invasive Disease-Free Survival (IDFS)	Oct 2027	Mar 2032

<sup>1</sup> CT.gov update in progress

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Lebrikizumab

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<a href="#">NCT05559359</a>	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1)	3	367	Percentage of Participants with an Investigator Global Assessment (IGA) score 0 or 1 and a Reduction ≥2 points from Baseline	Jan 2026	Dec 2026
<a href="#">NCT05735483</a>	Atopic Dermatitis	A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-2)	3	310	Percentage of Participants Discontinued From Study Treatment due to Adverse Events (AEs)	Dec 2027	Apr 2029
<a href="#">NCT06280716</a>	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis (ADvance-Asia)	3	301	Percentage of Participants Achieving Eczema Area and Severity Index (EASI-75) ≥75% Reduction in EASI Score for Mono Cohort	Sep 2025	Aug 2026
<a href="#">NCT06339008</a>	Perennial Allergic Rhinitis (PAR)	A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)	3	450	Mean Change From Baseline (CFBL) in Total Nasal Symptom Score (TNSS) at week 16	Sep 2026	Oct 2028
<a href="#">NCT06921759</a>	Atopic Hand and Foot Dermatitis	A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis (ADtouch)	3	206	Percentage of Participants Achieving a Hand and Foot Investigator Global Assessment (HF-IGA) Score of 0 or 1 with ≥2-point Improvement from Baseline	Jul 2026	Sep 2026
<a href="#">NCT06338995</a>	Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)	A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)	3	510	Mean Change From Baseline (CFBL) in Participant Reported Nasal Congestion Score (NCS) Severity	May 2027	Mar 2028

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Lepodisiran

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06292013	Atherosclerotic Cardiovascular Disease (ASCVD) <sup>1</sup>	A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	3	17300	Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite Endpoint	Mar 2029	Mar 2029

<sup>1</sup> Reduction of major adverse cardiovascular events (MACE) in patients with Atherosclerotic Cardiovascular Disease (ASCVD) and those at-risk for ASCVD

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Mirikizumab

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<a href="#">NCT04232553</a>	Crohn's Disease	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)	3	996	Percentage of Participants Achieving Endoscopic Response	Nov 2024	Apr 2027
<a href="#">NCT06937099</a>	Crohn's Disease	Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight (COMMIT-CD)	3	290	Percentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI), Endoscopic Remission, and at least 10% Weight Reduction	May 2028	May 2028
<a href="#">NCT03519945</a>	Ulcerative Colitis	A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT-3)	3	1063	Percentage of Participants in Clinical Remission	Jul 2026	Dec 2027
<a href="#">NCT06937086</a>	Ulcerative Colitis	Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (COMMIT-UC)	3	350	Percentage of Participants Who Simultaneously Achieve Clinical Remission and at Least 10% Weight Reduction	Apr 2028	Apr 2028

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Muvalaplin

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<a href="https://clinicaltrials.gov/ct2/show/NCT07157774">NCT07157774</a>	Elevated Lp(a)	Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) – (MOVE-Lp(a))	3	10450	Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite Endpoint	Mar 2031	Mar 2031

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Olomorrasib

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<a href="#">NCT06119581</a>	Carcinoma, Non-Small-Cell Lung	A Study of First-Line Olomorrasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01)	3	1016	Dose Optimization and Safety Lead-In Part B: Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE)	Oct 2026	Oct 2029
<a href="#">NCT06890598<sup>1</sup></a>	Carcinoma, Non-Small-Cell Lung	Study of Olomorrasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02)	3	700	Part A: Disease-Free Survival (DFS) by Investigator Assessment	May 2029	Feb 2032
<a href="#">NCT04956640<sup>2</sup></a>	Carcinoma, Non-Small-Cell Lung	Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)	1 2	540	Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy	Apr 2027	Apr 2027

<sup>1</sup> Also lists AstraZeneca; <sup>2</sup> Also lists Merck Sharp & Dohme LLC

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Orforglipron

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<a href="#">NCT05803421</a>	Type 2 Diabetes	A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)	3	2749	Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) [Myocardial Infarction (MI), Stroke, Hospitalization for Unstable Angina, or Cardiovascular (CV) Death]	Mar 2026	Mar 2026
<a href="#">NCT06948422</a>	Hypertension	A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension)	3	974	Change from baseline in systolic blood pressure	Sep 2027	Sep 2027
<a href="#">NCT05869903</a>	Obesity	A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)	3	3127	Mean Percent Change from Baseline in Body Weight	Jul 2025	Oct 2027
<a href="#">NCT06672939</a>	Obesity	A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities	3	125	Percent Change from Baseline in Body Mass Index (BMI)	Feb 2027	Mar 2027
<a href="#">NCT06972472</a>	Obesity	A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes	3	600	Change from Baseline in Hemoglobin A1c (HbA1c)	Jan 2027	Aug 2027
<a href="#">NCT06972459</a>	Obesity	A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity	3	600	Percent Change from Baseline in Body Weight	Jan 2027	Aug 2027

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Orforglipron (Cont.)

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06649045	OSA	A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ATTAIN-OSA)	3	600	Change from Baseline in Apnea-Hypopnea Index (AHI)	Nov 2026	Jan 2027
NCT07153471	Osteoarthritis	A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee (ATTAIN-OA PAIN)	3	800	Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score	Apr 2028	May 2028
NCT07202884	Stress Urinary Incontinence	A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight (RESTRAIN-SUI)	3	1000	Change from Baseline in Incontinence Episode Frequency (IEF)	Mar 2028	Mar 2028
NCT07241390	Atherosclerosis Cardiovascular Disease	A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)	3	7140	Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events	Aug 2031	Aug 2031
NCT07223593	Peripheral Arterial Disease	Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease (ATTAIN-PAD)	3	1205	Percent Change from Baseline in Maximum Walking Distance	Jun 2028	Jun 2028

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Pirtobrutinib

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04666038	Chronic Lymphocytic Leukemia	Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)	3	238	Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)	Aug 2023	May 2027
NCT05023980	Chronic Lymphocytic Leukemia	A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313)	3	309	To evaluate progression-free survival (PFS) of pirtobrutinib (Arm A) compared to bendamustine and rituximab (Arm B)	Jul 2025	Oct 2027
NCT04965493	Chronic Lymphocytic Leukemia	A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)	3	600	To evaluate progression-free survival (PFS) of pirtobrutinib plus venetoclax and rituximab (Arm A) compared to venetoclax and rituximab (Arm B)	Oct 2026	Oct 2027
NCT05254743	Chronic Lymphocytic Leukemia	A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-314)	3	662	Percentage of Participants Achieving Complete Response (CR), Complete Remission with Incomplete Hematologic Recovery (Cri), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR) Part 1	Jun 2025	Jan 2028
NCT04662255	Lymphoma, Mantle-Cell	Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN MCL-321)	3	500	To compare progression-free survival (PFS) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL)	Jan 2027	Apr 2028

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Pirtobrutinib (Cont.)

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<a href="#">NCT07162181</a>	Non-Hodgkin Lymphoma	Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers	2	13	Percentage of Participants with Grade 3 or Higher Treatment-emergent Adverse Events	May 2030	May 2030
<a href="#">NCT06721013</a>	Immune Thrombocytopenia (ITP)	A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia	1 2	58	Ph. 1 - Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Dec 2026	Feb 2027

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Remternetug

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<a href="#">NCT05463731</a>	Alzheimer's Disease	A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)	3	1667	Percentage of Participants Who Reach Amyloid Plaque Clearance on Amyloid PET Scan for Remternetug versus Placebo	Apr 2024	Mar 2026
<a href="#">NCT06653153</a>	Alzheimer's Disease	A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)	3	1400	Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rate Scale (CDR)	Apr 2029	Oct 2030

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Retatrutide

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<a href="#">NCT05929066</a>	Obesity	A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)	3	2300	Percent Change From Baseline in Body Weight	Apr 2026	May 2026
<a href="#">NCT05929079</a>	Obesity	A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2)	3	1000	Percent Change from Baseline in Body Weight	May 2026	May 2026
<a href="#">NCT05882045</a>	Obesity	A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)	3	1800	Percent Change from Baseline in Body Weight	Apr 2026	May 2026
<a href="#">NCT06383390</a>	Obesity	The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES)	3	10000	Time to First Occurrence of Composite Endpoints	Feb 2029	Feb 2029
<a href="#">NCT06662383</a>	Obesity	A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5)	3	800	Percent Change from Baseline in Body Weight	Dec 2026	Dec 2026

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Retatrutide (Cont.)

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT07035093	Obesity	A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7)	3	586	Percent Change from Baseline in Body Weight   Change from Baseline in Pain Intensity Per Numeric Rating Scale	Sep 2027	Sep 2027
NCT06859268	Obesity	A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity (TRIUMPH-6)	3	643	Percent Change from Baseline in Body Weight	Apr 2028	Apr 2028
NCT06354660	Type 2 Diabetes	Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)	3	480	Change from Baseline in Hemoglobin A1c (HbA1c)	Jan 2026	Feb 2026
NCT06260722	Type 2 Diabetes	Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)	3	1250	Change from Baseline in Hemoglobin A1c (HbA1c)	Aug 2026	Jan 2027
NCT06297603	Type 2 Diabetes	Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)	3	320	Change from Baseline in Hemoglobin A1c (HbA1c)	Oct 2026	Nov 2026

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Retatrutide (Cont.)

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<a href="#">NCT06982846</a>	Type 2 Diabetes Mellitus	A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia	1	78	Time-to-Event of Recovery of Plasma Glucose (PG) Concentration from 48 Milligram per Deciliter (48 mg/dL) to 70 mg/dL (tPG_nadir-70 mg/dL)	May 2026	May 2026
<a href="#">NCT06982859</a>	Diabetes Mellitus	A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus	1	95	Change from Baseline in Total Clamp Disposition Index (cDI) for Comparison of Retatrutide With Placebo	Nov 2026	Nov 2026

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Retevmo

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<a href="#">NCT04211337</a>	Medullary Thyroid Cancer	A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)	3	291	Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)	May 2023	Feb 2026
<a href="#">NCT04194944</a>	Non-Small Cell Lung Cancer	A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)	3	261	Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (With Pembrolizumab)	May 2023	Jun 2030
<a href="#">NCT03157128</a>	Non-Small Cell Lung Cancer	A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)	1 2	857	Phase 1: MTD, Incidence rate and category of dose limiting toxicities (DLTs) during the first 28-day cycle of LOXO-292 (selpercatinib) treatment	Feb 2025	Feb 2027
<a href="#">NCT04819100</a>	Carcinoma, Non-Small-Cell Lung	A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)	3	152	Event-Free Survival (EFS), EFS by Investigator Assessment in the Primary Analysis Population	Jan 2026	Apr 2028

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Sofetabart Mipitecan (FRa ADC)

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT07213804	Ovarian Neoplasms	A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (FRAmework-01)	3	1080	Progression-free Survival (PFS), PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator	Apr 2028	Aug 2031

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Taltz

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<a href="#">NCT06588283</a>	Psoriasis	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight (TOGETHER-PsO)	3	250	Percentage of Participants Who Simultaneously Achieved Psoriasis Area and Severity Index (PASI) 100 and At Least 10% Weight Reduction	Jan 2026	May 2026
<a href="#">NCT06588296</a>	Psoriatic Arthritis	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight (TOGETHER-PsA)	3	279	Percentage of Participants Who Simultaneously Achieved American College of Rheumatology (ACR) ACR50 and at Least a 10% Weight Reduction	Nov 2025	Apr 2026

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Tirzepatide

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<a href="#">NCT06047548</a>	Obesity	A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-MAINTAIN)	3	400	Percent Maintenance of Body Weight (BW) Reduction Achieved during the 60-Week Weight Loss Period	May 2026	May 2026
<a href="#">NCT06075667</a>	Obesity	A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS)	3	150	Percent Change from Baseline in Body Mass Index (BMI)	May 2026	Jul 2029
<a href="#">NCT06439277</a>	Obesity	A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)	3	300	Percent Change from Baseline in Body Mass Index (BMI)	Oct 2027	Dec 2030
<a href="#">NCT05556512</a>	Obesity	A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)	3	15374	Time to First Occurrence of Any Component Event of Composite (All-Cause Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Coronary Revascularization, or Heart Failure Events)	Oct 2027	Oct 2027
<a href="#">NCT07165028</a>	MASLD	A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)	3	4500	Time to First Occurrence of Any Component of the Composite Endpoint for Major Adverse Liver Outcomes (MALO)	Aug 2030	Aug 2032

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Tirzepatide (Cont.)

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<a href="#">NCT06914895<sup>1</sup></a>	Type 1 Diabetes	A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight	3	905	Change from Baseline in Hemoglobin A1c (HbA1c)	May 2027	May 2027
<a href="#">NCT06962280<sup>1</sup></a>	Type 1 Diabetes	A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight	3	465	Change from Baseline in Hemoglobin A1c (HbA1c)	Apr 2027	Dec 2027
<a href="#">NCT06037252</a>	Type 2 Diabetes	A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity	2	350	Percent Change From Baseline in Body Weight	Jan 2026	Oct 2026
<a href="#">NCT05536804</a>	CKD	A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TREASURE-CKD)	2	140	Change from Baseline in Kidney Oxygenation in Participants With or Without T2D	Sep 2026	Oct 2026

<sup>1</sup> CT.gov update in progress

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Verzenio

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
<a href="#">NCT03155997<sup>1</sup></a>	Breast Cancer	Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)	3	5637	Invasive Disease-Free Survival (IDFS)	Mar 2020	May 2029
<a href="#">NCT05169567</a>	Breast Neoplasm	Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMonarch)	3	368	Progression-Free Survival (PFS)	Feb 2024	Dec 2027

<sup>1</sup> Also lists NSABP Foundation Inc

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Early Phase Cardiometabolic Health

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Bimagrumab	<a href="#">NCT07030127</a>	Healthy	A Study of LY3985863 in Healthy Participants	1	24	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Apr 2026	Apr 2026
Bimagrumab	<a href="#">NCT06643728</a>	Obesity	A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight	2	240	Percent Change from Baseline in Body Weight	Apr 2026	Jan 2027
GGG Tri-Agonist III	<a href="#">NCT06945419</a>	Healthy	A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes	1	201	Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration	Apr 2026	Apr 2026
GS Insulin Receptor Agonist	<a href="#">NCT07215312</a>	Type 2 Diabetes Mellitus	A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin	2	100	Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis)	Nov 2026	Dec 2026
GS Insulin Receptor Agonist	<a href="#">NCT06280703</a>	Healthy	A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)	1	118	Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration	Sep 2026	Sep 2026

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Early Phase Cardiometabolic Health (Cont.)

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
LA-ANP	<a href="#">NCT06148272</a>	Healthy	A Study of LY3971297 in Healthy Participants	1	225	Part A and F: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Sep 2026	Sep 2026
Macupatide	<a href="#">NCT07215559</a>	Obesity	A Study of Macupatide (LY3532226) and Eloraltide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes	2	200	Percent Change from Baseline in Body Weight	Mar 2027	May 2027
Nisotirostide	<a href="#">NCT06897475</a>	Type 2 Diabetes	A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide	2	240	Change from Baseline in Hemoglobin A1c (HbA1c)	Dec 2026	Jan 2027
Naperiglipron	<a href="#">NCT06683508</a>	Obesity	A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight	2	275	Percent Change from Baseline in Body Weight	Apr 2026	Sep 2026
PNPLA3 siRNA	<a href="#">NCT05395481</a>	Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)	A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	1	176	Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration	May 2026	May 2026

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Early Phase Cardiometabolic Health (Cont.)

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Solbinsiran	<a href="#">NCT07269210</a>	Severe Hypertriglyceridemia	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 (Solbinsiran) in Adults With Severe Hypertriglyceridemia	2	60	Change from Baseline in Triglycerides	Mar 2027	Aug 2027
ANGPTL3 EDITOR ASCVD	<a href="#">NCT06451770</a>	Hypercholesterolemia	Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia	1	36	Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)	Dec 2027	Dec 2027
PCSK9 EDITOR ASCVD	<a href="#">NCT06164730</a>	Heterozygous Familial Hypercholesterolemia	A Study of VERVE-102 in Patients with Familial Hypercholesterolemia or Premature Coronary Artery Disease	1	85	Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)	Aug 2026	Aug 2027

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Early Phase Immunology

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Eltrekitabart	<a href="#">NCT06046729</a>	Hidradenitis Suppurativa	A Study of Eltrekitabart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	2	352	Percentage of Participant Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)	Sep 2025	Aug 2026
Eltrekitabart	<a href="#">NCT06598943</a>	Ulcerative Colitis	A Study of Eltrekitabart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis	2	140	Percentage of Participants Achieving Clinical Remission	Dec 2027	Sep 2028
INTEGRIN $\alpha 4\beta 7$ (MORF-057)	<a href="#">NCT05611671</a>	Ulcerative Colitis	A Study to Evaluate MORF-057 in Adults with Moderately to Severely Active UC (EMERALD-2)	2	280	Proportion of participants in clinical remission at Week 12 as determined using the Modified Mayo Clinic Score (mMCS)	Nov 2024	Aug 2026
INTEGRIN $\alpha 4\beta 7$ (MORF-057)	<a href="#">NCT07186101</a>	Ulcerative Colitis	LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis (TOPAZ-UC)	2	252	Percentage of Participants Who Achieve Clinical Remission with Modified Mayo Score (mMS)	May 2027	Mar 2029
INTEGRIN $\alpha 4\beta 7$ (MORF-057)	<a href="#">NCT06226883</a>	Crohn's Disease	A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (GARNET)	2	385	Proportion of participants with endoscopic response at Week 14 determined using the Simple Endoscopic Score-CD (SES-CD)	Nov 2026	Aug 2028

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Early Phase Immunology (Cont.)

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Ocadusertib <sup>1</sup>	<a href="#">NCT05848258</a>	Rheumatoid Arthritis	An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis	2	380	Phase 2a: Change from Baseline in Disease Activity Score - high-sensitivity C-reactive protein (DAS28-hsCRP)	Feb 2026	Jul 2026

<sup>1</sup> Also lists Rigel Pharmaceuticals

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Early Phase Neuroscience

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Anti-VEGF Gene Therapy	<a href="#">NCT06517888</a>	Vestibular Schwannoma	Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma	1 2	27	AEs with relationship to the investigational medicinal product and/or to the administration procedure (including the delivery device)	Aug 2029	Aug 2029
Epiregulin Ab	<a href="#">NCT06568042</a>	Neuropathic Pain	Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy	2	450	Mean Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS)	Jun 2026	Sep 2026
GBA1 Gene Therapy	<a href="#">NCT04127578</a>	Parkinson's Disease	Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)	1 2	32	Cumulative number of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Dec 2030	Dec 2030
GBA1 Gene Therapy	<a href="#">NCT05487599</a>	Gaucher Disease	A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)	1 2	15	Incidence and severity of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Nov 2031	Nov 2031
MAPT siRNA	<a href="#">NCT06297590</a>	Alzheimer's Disease	A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease	1	48	Number of participants with one or more Adverse Event (s) (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration	Feb 2027	Feb 2027

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Early Phase Neuroscience (Cont.)

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Mazdutide	<a href="#">NCT06817356</a>	Alcohol Use Disorder	A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder	2	300	Behaviors Associated with Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method	Aug 2026	Aug 2026
Mevidalen	<a href="#">NCT06538116</a>	Alzheimer's Disease	A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease	2	300	Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS)	May 2026	May 2026
Nav1.8 INH	<a href="#">NCT07339722</a>	Healthy	A Study of LY4515100 in Healthy Participants	1	40	Number of participants with one or more serious adverse event(s) (SAEs) of LY4515100	Jul 2026	Jul 2026
OTOF Gene Therapy	<a href="#">NCT05821959</a>	Sensorineural Hearing Loss, Bilateral	Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss	1 2	22	Frequency of Adverse Events (AEs)	Oct 2028	Oct 2028
SNCA siRNA	<a href="#">NCT06565195</a>	Parkinson's Disease	A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease (PROSPECT)	1	108	Incidence of Serious Adverse Events (SAEs)	May 2029	May 2029
UNC13A SSO ALS	<a href="#">NCT07100119</a>	Amyotrophic Lateral Sclerosis	A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis	1	32	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration	Aug 2027	Sep 2027

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Early Phase Oncology

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
GIPR Agonist LA	<a href="#">NCT07169851</a>	Nausea	A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer	2	204	Proportion of Participants with a Complete Response (CR) in the Delayed Phase of CINV	Sep 2026	Sep 2026
KRAS G12D	<a href="#">NCT06586515</a>	Pancreatic Ductal Adenocarcinoma	A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors (MOONRAY-01)	1	630	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Mar 2029	Mar 2029
Nectin-4 ADC 1	<a href="#">NCT06238479</a>	Metastatic Solid Tumor	A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors (EXCEED)	1	490	Phase 1a: To determine the recommended dose of LY4101174: Number of participants with dose-limiting toxicities (DLTs)	Mar 2027	Mar 2027
Nectin-4 ADC 2	<a href="#">NCT06465069</a>	Metastatic Solid Tumor	A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors	1	420	Phase 1a: To determine the recommended phase 2 dose (RP2D) optimal dose(s) of LY4052031	May 2027	May 2027
PAN KRAS	<a href="#">NCT06607185</a>	Pancreatic Ductal Adenocarcinoma	A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors	1	750	Number of Participants with Dose-limiting Toxicities (DLTs)	Jan 2030	Jan 2030

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Select Trials – Early Phase Oncology (Cont.)

Source: [clinicaltrials.gov](https://clinicaltrials.gov), January 23, 2026

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
SMARCA2 (BRM)	<a href="#">NCT06561685</a>	Metastatic Solid Tumor	A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors	1	340	Phase 1a: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs)	Oct 2027	Oct 2027
TERSOLISIB (PI3K $\alpha$ INH (STX-478)	<a href="#">NCT05768139</a>	Breast Cancer	First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (PIKALO-1)	1 2	720	Number of participants who experience at least 1 Dose Limiting Toxicity (DLT)	Jul 2030	Jul 2030
PTK7 ADC	<a href="#">NCT07046923</a>	Carcinoma, Non-Small-Cell Lung	A Study of LY4175408 in Participants With Advanced Cancer	1	240	Phase 1a-Number of Participants with Dose Limiting Toxicities of LY4175408	Jul 2030	Jul 2030
VEPUGRATINIB	<a href="#">NCT05614739</a>	Urinary Bladder Neoplasms	A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 (FORAGER-1)	1	535	Phase 1a: To determine the recommended dose of LOXO-435: Safety, number of participants with dose-limiting toxicities (DLTs)	Jun 2027	Jun 2027

\* Molecule may have multiple indications. \*\* Trial may have additional primary and other secondary outcomes

# Trademarks

All trademarks and trade names referred to in this earnings update are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this earnings update, the property of their respective owners. Solely for convenience, the trademarks and trade names in this earnings update are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.